APA (7th ed.) Citation

Pavlakis, E., Neumann, M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., . . . Stiewe, T. (2023). Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: A druggable target for inhibiting integrin-α5-driven metastasis. Journal of Experimental & Clinical Cancer Research (17569966), 42(1), 1. https://doi.org/10.1186/s13046-023-02785-z

Chicago Style (17th ed.) Citation

Pavlakis, Evangelos, Michelle Neumann, Nastasja Merle, Ronja Wieboldt, Michael Wanzel, Viviane Ponath, Elke Pogge von Strandmann, Sabrina Elmshäuser, and Thorsten Stiewe. "Mutant P53-ENTPD5 Control of the Calnexin/calreticulin Cycle: A Druggable Target for Inhibiting Integrin-α5-driven Metastasis." Journal of Experimental & Clinical Cancer Research (17569966) 42, no. 1 (2023): 1. https://doi.org/10.1186/s13046-023-02785-z.

MLA (9th ed.) Citation

Pavlakis, Evangelos, et al. "Mutant P53-ENTPD5 Control of the Calnexin/calreticulin Cycle: A Druggable Target for Inhibiting Integrin-α5-driven Metastasis." Journal of Experimental & Clinical Cancer Research (17569966), vol. 42, no. 1, 2023, p. 1, https://doi.org/10.1186/s13046-023-02785-z.